PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34803090-4 2021 We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. alectinib 48-57 ret proto-oncogene Homo sapiens 74-77 34803090-4 2021 We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. alectinib 48-57 ret proto-oncogene Homo sapiens 114-117 34803090-5 2021 Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. alectinib 72-81 ret proto-oncogene Homo sapiens 4-7